trending Market Intelligence /marketintelligence/en/news-insights/trending/4VlyuT2usViqGbcMqYC__g2 content esgSubNav
In This List

Hutchison China MediTech seeks regulatory approval for cancer drug

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise

Blog

Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises


Hutchison China MediTech seeks regulatory approval for cancer drug

Hutchison China MediTech Ltd. filed an application with the China Food and Drug Administration, seeking approval for fruquintinib in patients with advanced colorectal cancer.

The application is supported by data from a successful phase 3 trial.

The submission also triggers a $4.5 million milestone payment from Eli Lilly & Co., which is co-developing the drug in China.